Introduction {#S0001}
============

Mitral regurgitation (MR) is the most common disease of the mitral valve and the second most common valvular heart disease after aortic stenosis. The MR of at least moderate degree is present in 15-30% of patients with congestive heart failure and in up to 12% of patients who underwent myocardial infarction during the preceding month \[[@CIT0001]\]. Its incidence increases with age, which becomes more and more important due to the aging of the general population \[[@CIT0002]\]. The most frequent causes of MR include degenerative changes of the valvular apparatus and functional MR in the course of ischemic heart disease and cardiomyopathy. Additionally, MR may be caused by infective endocarditis or rheumatic fever. For many years cardiac surgery has been the only method of treatment of hemodynamically significant valvular heart diseases, including mitral valve diseases. New valvular prostheses, meticulous surgical techniques, including a variety of repair procedures and minimally invasive treatments and years of experience of the operators guarantee low morbidity and mortality. However, the development and miniaturization of the equipment, similar to the one observed for aortic valve procedures, permit the use of less invasive techniques also for the treatment of the mitral valve. Additionally, almost 1/3 of patients with MR are at high risk of surgery caused mainly by the advanced age, impaired left ventricular function and the presence of comorbidities \[[@CIT0003]\].

All-cause mortality after surgical procedures on the mitral valve in patients above 75 years of age undergoing concomitant bypass grafting reaches 14% \[[@CIT0004]\]. This is an additional stimulus for the development of alternative forms of therapy and indicates a target group which may benefit from them. Intensive development of non-surgical techniques of MR treatment and transluminal interference into the complicated structure of the mitral apparatus, which is more complex than the aortic apparatus, has only been possible for the last few years. Some techniques, such as introduction of systems aimed at restoration of normal mitral annulus diameter through the coronary sinus, did not fully bring the expected results and are still at the early clinical phase. A new promising method is the MitraClip system, the idea of which is derived from the surgical technique proposed by Alfieri in the year 1991 \[[@CIT0005]\]. The procedure is based on transluminal connection of the regurgitant mitral valve leaflets by means of one (or less frequently more) dedicated cobalt-chromium clips. Connected leaflets form a dual and reduced valvular orifice and the mitral valve becomes a double-orifice valve. The procedure is performed in the hybrid catheterization laboratory or in the catheterization laboratory under general anesthesia (although it is possible to perform a procedure under sedation and local anesthesia) and with fluoroscopic and transesophageal echocardiographic control. A multidisciplinary team consists of 2 interventional cardiologists, a person performing echocardiography, an anesthesiologist and trained nurses. The procedure has been used for patients with degenerative and functional forms of MR. Feldman *et al*. were the first to report the results of the first procedures using the MitraClip system in humans \[[@CIT0006]\]. Detailed methodology and the first positive Polish results of the in-hospital observation were presented by the center in Zabrze in 2010 \[[@CIT0007]\] and the role of echocardiography, which is crucial for qualification and monitoring of the MitraClip procedures, was described by the authors from Bydgoszcz \[[@CIT0008]\]. We present direct and 90-day results of treatment of the first 3 patients in our center.

Case report {#S0002}
===========

Three patients qualified for the procedure using the MitraClip in our center had a severe post-myocardial infarction heart failure (NYHA class III or IV) with enlarged left ventricle and coexisting significant functional MR ([Table 1](#T0001){ref-type="table"}). Concomitant diseases worth mentioning included chronic renal failure stage 3 in all patients, chronic atrial fibrillation in 2 patients, diabetes mellitus, hepatic cirrhosis and pancytopenia caused by hypersplenism in 1 patient. In all patients the surgical risk of MR treatment was considered high. The procedures were performed in the catheterization laboratory under general anesthesia with cardiac surgeons and operating room on-call. The system for inter-atrial septal puncture with the Mullins sheath and the Brockenbrough needle was introduced through the right femoral vein and inferior vena cava. The inter-atrial septum was punctured under transesophageal echocardiography control at its upper part and high enough to permit correct introduction of the Guide Catheter and the MitraClip system with the clip to the left atrium perpendicularly to the orifice plane of the mitral valve ([Figure 1](#F0001){ref-type="fig"}). The next steps required precise imaging by means of transesophageal echocardiography as presented in [Figure 2](#F0002){ref-type="fig"}. The Guide Catheter with open clips was placed axially in the mitral valve orifice and then introduced below the level of the leaflet coaptation in the central part of the regurgitant jet ([Figure 3](#F0003){ref-type="fig"}). Retraction of the system permitted two leaflets to be caught and the clip to be closed. This stage of the procedure might have been repeated in order to optimally catch the leaflets. After obtaining a satisfactory effect on echocardiographic assessment a closed clip was released ([Figure 4](#F0004){ref-type="fig"}) and the system was removed from the body. The mean time of the procedure was 5 h and 40 min (4 to 6 and a half h) with a mean fluoroscopy time of 36 min (34-37 min). One patient suffered from lower respiratory tract infection in the post-procedural phase, which required therapy with antibiotics. No local vascular complications or deterioration of renal failure were observed. There was an improvement of exercise capacity assessed by NYHA class and a mild increase of LVEF in all patients at 3 months after the procedure ([Table 2](#T0002){ref-type="table"}). In 2 patients a significant reduction of the MR degree and pulmonary hypertension were noted ([Figures 5A](#F0005){ref-type="fig"}, [B](#F0005){ref-type="fig"}). In 1 patient quite severe mitral regurgitation persisted despite fixation of two leaflets by the clip ([Figures 5C](#F0005){ref-type="fig"}, [D](#F0005){ref-type="fig"}). The effect of this procedure has to be considered as non-optimal despite a subjective improvement of exercise capacity reported by the patient. The patient has been considered as a potential candidate for the introduction of a second clip. In addition, during 3 months of observation 1 patient suffered from decompensated heart failure caused by an episode of atrial flutter with rapid ventricular rhythm, which was successfully treated with pharmacotherapy.

![Puncture of the inter-atrial septum visible on transesophageal echocardiography](PWKI-9-20890-g001){#F0001}

![Successive steps of MitraClip implantation visible on transesophageal echocardiography: **A** -- Visible initially large regurgitant jet across the mitral valve. **B** -- Placement of the MitraClip system axially to the mitral orifice. **C** -- Catching of the two valvular leaflets by the clip. **D** -- Reduction of the regurgitant jet after closure of the clip and retraction of the MitraClip system](PWKI-9-20890-g002){#F0002}

![The MitraClip system at the level of the mitral valve during positioning](PWKI-9-20890-g003){#F0003}

![The clip released from the delivery set fixing the leaflets of the mitral valve](PWKI-9-20890-g004){#F0004}

![Comparison of the mitral regurgitation range before the procedure and 90 days after the procedure of MitraClip implantation. **A, B** -- Good effect of the procedure. **C, D** -- Non-optimal effect of the procedure](PWKI-9-20890-g005){#F0005}

###### 

Clinical and echocardiographic characteristics of patients undergoing MitraClip implantation

  Variable                                        Patient 1                   Patient 2                   Patient 3
  ----------------------------------------------- --------------------------- --------------------------- ---------------------------
  Age \[years\]                                   62                          78                          59
  Sex                                             M                           F                           M
  Coronary artery disease                         1 × myocardial infarction   1 × myocardial infarction   1 × myocardial infarction
  2 × PCI                                         1 × PCI                     1 × CABG, 3 × PCI           
  Logistic EuroSCORE \[%\]                        19.2                        30.2                        36.2
  ECG                                             Sinus rhythm, LBBB          AF, LBBB                    AF
  Type of regurgitation according to Carpentier   I, IIIB                     I, IIIB                     I, IIIB
  Etiology of the regurgitation                   Ischemic                    Ischemic                    Ischemic
  Effective regurgitant orifice area \[cm^2^\]    0.4                         0.4                         0.5
  Vena contracta width \[mm\]                     7                           7                           7
  Regurgitant volume \[ml\]                       60                          45                          86
  Mitral annulus diameter \[mm\]                  38                          38                          39
  Leaflet coaptation depth \[mm\]                 10.5                        10                          7.5
  Leaflet coaptation length \[mm\]                2.5                         2.5                         2.6

AF -- atrial fibrillation, CABG -- coronary artery bypass grafting, LBBB -- left bundle branch block, F -- female, M -- male, PCI -- percutaneous coronary intervention

###### 

Clinical and echocardiographic results of 90-day observation after MitraClip implantation

  Variable                                            Patient 1   Patient 2   Patient 3                  
  --------------------------------------------------- ----------- ----------- ----------- -------- ----- --------
  NYHA class                                          III         II          III/IV      II/III   III   II
  LVEF \[%\]                                          18          25          28          30       25    30
  LVEDD \[mm\]                                        72          72          70          63       64    62
  LVEDV \[ml\]                                        265         233         217         185      200   201
  Regurgitant jet                                     +++         +/++        +++/++++    ++       +++   ++/+++
  Diastolic mitral gradient \[mm Hg\]                             5/2                     7/2            8/3
  Valvular area in diastole (planimetric) \[cm^2^\]   6.2         3.6         5.0         1.5      5.1   1.4
  Systolic tricuspid gradient \[mm Hg\]               62          38          32          23       32    28
  RAP \[mm Hg\]                                       15          15          15          8        15    15

LVEF -- left ventricular ejection fraction, LVEDD -- left ventricular end-diastolic diameter, LVEDV -- left ventricular end-diastolic volume, NYHA -- New York Heart Association, RAP -- right atrial pressure

Discussion {#S0003}
==========

In recent years there has been dynamic development of percutaneous techniques used to treat structural heart diseases, including those involving the mitral valve. Currently, the key question is which patients will benefit most from percutaneous treatment of significant MR and how to select this group. The first broader experience was obtained from the American EVEREST study and its continuation, EVEREST II, in which patients with significant MR suitable for percutaneous and surgical treatment were randomized to one of those methods \[[@CIT0009]\]. Anatomic criteria included LVEF \> 25%, left ventricular end-systolic diameter \< 55 mm, mitral valve orifice area \> 4 cm^2^, central regurgitation jet related to A2/P2 segment of the valve, coaptation length ≥ 2 mm, and coaptation depth ≤ 11 mm. The main result at 2 years was that percutaneous treatment is significantly less effective in reduction of regurgitation, but safer than surgery and equally effective in terms of clinical assessment. One of the arms of this study, EVEREST II HRS, focused on patients at the highest risk of surgery including those with impaired left ventricular systolic function, which was a population similar to the 3 cases presented here. A control group consisted of patients with similar clinical characteristics, who were not included in the study \[[@CIT0010]\]. At 1 year patients who received a clip had higher survival in comparison to those treated conservatively (76% vs. 55%) and better exercise capacity with maximal MR of 2^nd^ degree achieved in 78% of patients. A reduction of left ventricular end-systolic and end-diastolic volume was also observed. However, this was not a randomized clinical trial. The European experiences come mainly from the German and Italian registries and the largest international ACCESS-EUROPE registry, whose initial results were presented during the congress of the European Society of Cardiology in 2012. In the registry conducted by Franzen *et al*. 51 patients who qualified for treatment with the MitraClip had severe MR and high risk of surgery (logistic EuroSCORE \> 20, STS score \> 12) with relatively few inclusion criteria in comparison to the EVEREST trial. Implantation of the MitraClip was successful in 96% of patients with post-procedural MR reduction by at least 1 degree in 31% of patients, by 2 degrees in 47% and by 3 degrees in 18% \[[@CIT0011]\]. The largest German registry included 481 patients, 93% of them in NYHA class III or IV, with mean logistic EuroSCORE of 23%. The MR reduction to mild or moderate degree was achieved in 94% of patients, exercise capacity improvement to NYHA class I or II after a mean of 85 days was observed in 64% of patients, and mortality rate was 12.5% \[[@CIT0012]\]. Tamburino *et al*. presented results of treatment of significant MR with MitraClip implantation in a group of 31 patients also at high risk of classic surgery. All procedures were successful and significant complications consisted of 1 cardiac tamponade and 1 non-cardiac death. At 30 days there was beneficial remodeling of the left ventricle with reduction of the mitral annulus diameter on echocardiography \[[@CIT0013]\]. The ACCESS-EUROPE registry included a total of 567 patients age 74 ±10 years mostly with numerous concomitant diseases (logistic EuroSCORE 23 ±18%) from 14 European centers. One-year survival after MitraClip implantation was 82% with the majority of patients reporting clinical improvement -- NYHA class I/II in 72% of patients, 6-minute walk distance increased by a mean of 60.5 m, and 79% of patients had MR \< 3^rd^ degree \[[@CIT0014]\]. It is too early to draw definite conclusions. The most recent guidelines of the European Society of Cardiology on the management of heart failure refer to percutaneous treatment of significant MR in patients not qualified for the surgery as a method used to reduce symptoms \[[@CIT0015]\]. However, there are no large randomized trials including a high-risk population and comparing percutaneous treatment to both surgery and conservative treatment as in the PARTNER study in patients with aortic stenosis. It is necessary to assess the durability of the mitral clips in long-term observation and in comparison to cardiac surgery of the mitral valve as well as their assessment in relation to MR etiology. The EVEREST II study included mainly patients with degenerative form of MR and a minority with functional form and moderate risk of surgery. The gap is supposed to be filled by starting studies known as RESHAPE-HF and COAPT including patients at high risk of surgery and a longer observation time. Besides, the anatomic structure and mechanics of the mitral valve are far more complicated in comparison to the aortic valve. In 1 of our patients it was impossible to successfully reduce the valvular regurgitation; however, it is highly probable that implantation of another clip would have improved the effect. As of today, the MitraClip is not a universal and reliable method, but it seems a safe option with low risk of complications. Successive generations of the device and increasing experience may improve the efficacy of this technique and the experience obtained may be necessary for the procedures of transluminal mitral valve implantation -- the first procedure of this kind in a human was performed in June 2012 in Copenhagen \[[@CIT0016]\]. As the results of surgery in patients with degenerative form of MR are characterized by high durability \[[@CIT0017]\], it seems probable that the group of patients who will benefit most consists of selected patients with functional ischemic MR including patients after previous revascularization procedures and those with impaired left ventricular function. In these patients surgical treatment in not an attractive option and this is not a small group. Exactly these types of patients (with post-infarction myocardial impairment, after numerous revascularization procedures) were treated in our center. The suggestions presented above are based on the results of the ACCESS-EUROPE registry and the multicenter observational PERMIT-CARE study, which included 51 patients with symptoms of heart failure, with functional MR and in whom resynchronization therapy was unsuccessful. The use of the MitraClip system in this group of patients improved exercise capacity and the left ventricular ejection fraction and led to reduction of the left ventricular volume in 70% of patients \[[@CIT0018]\]. It is unknown whether reduction of MR ≤ 2^nd^ degree and lack of annuloplasty, performed routinely during surgical repair, are effective enough, especially in the long term. Long-term observations after cardiac surgery demonstrate that persistence of more than mild MR and lack of annuloplasty are predictors of reoperation, but did not influence the mortality \[[@CIT0019], [@CIT0020]\]. Transluminal procedures have became competitive to cardiac surgery due to their less invasive nature and smaller trauma, lack of the need for deep general anesthesia or extracorporeal circulation, and a very short time to mobilization of a patient after the procedure with shorter duration of hospital stay. The word "competition" should be replaced by the word "cooperation". International medical societies emphasize the need for joined consultations and qualification for the optimal method of treatment for the individual patient performed by interdisciplinary teams called Heart Teams and regarding not only the choice of the revascularization modality, but also the method of treatment of valvular heart diseases.

Conclusions {#S0004}
===========

Percutaneous reduction of mitral regurgitation using the MitraClip system seems to be a safe procedure with low risk of complications. Full assessment of its efficacy and durability as well as full characterization of the target population for whom the MitraClip should be dedicated requires conduction of randomized trials and long-term observation of large groups of patients.
